Interferon Signaling in Neurodegeneration

Interferon Signaling in Neurodegeneration

Introduction

Type I interferons (IFN-I), originally characterized as antiviral cytokines, have emerged as potent drivers of neuroinflammation and neurodegeneration across multiple diseases including [Alzheimer's disease](/diseases/alzheimers-disease), [Parkinson's disease](/diseases/parkinsons-disease), [ALS](/diseases/als), and [Huntington's disease](diseases/huntingtons). The cGAS-STING pathway, a cytosolic DNA sensing system, serves as a major upstream activator of IFN-I production in the aging and diseased brain. This mechanism page provides a comprehensive overview of interferon signaling pathways, their role in neurodegenerative diseases, and therapeutic implications.[@interferon]

Overview of Interferon Signaling

The Type I Interferon Family

The type I interferon family comprises multiple cytokines that share structural homology and signaling pathways:[@cgassting]

IFN-α subtypes: At least 13 structurally related proteins (IFN-α1, IFN-α2, etc.)

IFN-β: A single isoform with potent antiviral activity

IFN-ε, IFN-κ, IFN-ω: Less characterized subtypes with tissue-specific functions

All type I IFNs signal through a common heterodimeric receptor composed of IFNAR1 and IFNAR2 subunits. This receptor is expressed on virtually all cell types, including neurons, astrocytes, microglia, and oligodendrocytes.

JAK-STAT Signaling Cascade

Receptor engagement triggers a well-characterized signaling cascade:[@microglial]

...

Interferon Signaling in Neurodegeneration

Introduction

Type I interferons (IFN-I), originally characterized as antiviral cytokines, have emerged as potent drivers of neuroinflammation and neurodegeneration across multiple diseases including [Alzheimer's disease](/diseases/alzheimers-disease), [Parkinson's disease](/diseases/parkinsons-disease), [ALS](/diseases/als), and [Huntington's disease](diseases/huntingtons). The cGAS-STING pathway, a cytosolic DNA sensing system, serves as a major upstream activator of IFN-I production in the aging and diseased brain. This mechanism page provides a comprehensive overview of interferon signaling pathways, their role in neurodegenerative diseases, and therapeutic implications.[@interferon]

Overview of Interferon Signaling

The Type I Interferon Family

The type I interferon family comprises multiple cytokines that share structural homology and signaling pathways:[@cgassting]

IFN-α subtypes: At least 13 structurally related proteins (IFN-α1, IFN-α2, etc.)

IFN-β: A single isoform with potent antiviral activity

IFN-ε, IFN-κ, IFN-ω: Less characterized subtypes with tissue-specific functions

All type I IFNs signal through a common heterodimeric receptor composed of IFNAR1 and IFNAR2 subunits. This receptor is expressed on virtually all cell types, including neurons, astrocytes, microglia, and oligodendrocytes.

JAK-STAT Signaling Cascade

Receptor engagement triggers a well-characterized signaling cascade:[@microglial]

Receptor binding: IFN-I binds the extracellular domains of IFNAR1 and IFNAR2, inducing receptor dimerization

JAK activation: Associated tyrosine kinases JAK1 and TYK2 are phosphorylated

STAT phosphorylation: STAT1 and STAT2 undergo tyrosine phosphorylation

ISGF3 formation: Phosphorylated STAT1 and STAT2 associate with IRF9 to form the ISGF3 complex

Nuclear translocation: ISGF3 translocates to the nucleus

Gene activation: ISGF3 binds to interferon-stimulated response elements (ISRE) in promoter regions

This cascade activates hundreds of interferon-stimulated genes (ISGs) encoding proteins involved in antiviral defense, immune modulation, cell survival, and inflammation.

Interferon-Stimulated Genes

The ISG repertoire includes:[@jakstat]

Antiviral effectors: MX1, OAS1/RNase L, IFIT family

Immunomodulatory proteins: CXCL10, CCL5, IL-6

Complement components: C1q, C3, C4

Antigen presentation machinery: MHC class I and II

Apoptotic regulators: caspases, BIM, PUMA

In the context of neurodegeneration, chronic ISG activation drives sustained inflammation, complement-mediated synapse elimination, and neuronal death.

Pathway Diagram

The cGAS-STING Pathway

Mechanism of Cytosolic DNA Sensing

The cGAS-STING pathway serves as the principal sensor of cytosolic DNA:[@trem]

DNA binding: cGAS binds double-stranded DNA (dsDNA) in the cytosol through its DNA-binding domain

cGAMP synthesis: DNA-bound cGAS undergoes conformational change and catalyzes synthesis of cyclic GMP-AMP (cGAMP) from ATP and GTP

STING activation: cGAMP binds to STING (Stimulator of Interferon Genes) in the endoplasmic reticulum membrane

Trafficking: STING-cGAMP complex translocates from ER to Golgi apparatus

TBK1 activation: Kinase TBK1 is recruited and activated

IRF3 phosphorylation: TBK1 phosphorylates IRF3 transcription factor

IFN transcription: Phosphorylated IRF3 dimerizes and translocates to nucleus

Sources of Activating DNA in Neurodegeneration

Multiple sources of cytosolic DNA activate cGAS in neurodegenerative diseases:[^6]

Retrotransposon activation: Aging-associated derepression of endogenous retroviruses and retrotransposons

Mitochondrial DNA release: Mitochondrial dysfunction and permeability transition

Nuclear envelope leakage: Age-related nuclear envelope deterioration

DNA damage accumulation: Impaired DNA repair mechanisms

Microbial DNA: Persistent infections or gut microbiome translocation

Interferon Signaling in Alzheimer's Disease

Pathogenic Mechanisms

In Alzheimer's disease, multiple mechanisms drive chronic IFN-I activation:[^7]

Amyloid-β-cGAS interaction: Aβ aggregates can serve as a platform for cGAS activation, providing a scaffold for DNA binding[^8]

Tau pathology-induced DNA damage: Hyperphosphorylated tau disrupts nuclear integrity and DNA repair, leading to cytosolic DNA accumulation[^9]

Mitochondrial dysfunction: Aβ and tau pathology impair mitochondrial function, causing mtDNA release into cytosol[^10]

Microglial senescence: Aging microglia show increased baseline cGAS activation

Blood-brain barrier disruption: Peripheral IFN-I can enter CNS through compromised BBB

Consequences for AD Pathogenesis

Chronic IFN-I signaling contributes to multiple aspects of AD pathophysiology:[^11]

Microglial hyperactivation: Sustained IFN-I transforms microglia into a pro-inflammatory state

Synaptic elimination: IFN-I-induced complement activation drives synapse pruning

Neuronal dysfunction: Direct effects on neuronal calcium homeostasis and mitochondrial function

Impaired neurogenesis: IFN-I inhibits hippocampal neurogenesis

Network dysfunction: Altered neuronal excitability and connectivity

Evidence from Human Studies

Post-mortem brain studies reveal:[^12]

• Increased ISG expression in AD temporal cortex
• Elevated cGAS and STING in microglia surrounding amyloid plaques
• Correlation between IFN-I signatures and disease severity
• C1q upregulation in AD brains as marker of complement activation

Interferon Signaling in Parkinson's Disease

Dopaminergic Neuron Vulnerability

The cGAS-STING pathway is particularly relevant in PD due to the unique vulnerability of dopaminergic neurons:[^13]

α-Synuclein pathology: Pathological α-synuclein aggregates can activate cGAS-STING[^14]

Mitochondrial vulnerability: Dopaminergic neurons have high mitochondrial demands and are particularly susceptible to mtDNA release

PINK1/Parkin dysfunction: Mutations in these genes impair mitophagy, leading to mitochondrial DNA release[^15]

LRRK2 mutations: LRRK2 G2019S enhances STING-dependent IFN-I signaling[^16]

Neuromelanin interaction: Neuromelanin can bind DNA and activate cGAS

Microglial IFN-I Response

Chronic microglial activation in PD includes robust IFN-I signaling:[^17]

Sustained ISG expression: MX1, OAS1 elevated in PD substantia nigra

Pro-inflammatory cytokine production: TNF-α, IL-1β, IL-6

Antigen presentation: Upregulated MHC class II

Phagocytic dysfunction: Impaired α-synuclein clearance

Impact on Disease Progression

IFN-I signaling accelerates PD progression through:

Enhanced neuroinflammation: Perpetuates microglial activation

α-Synuclein spreading: IFN-I may promote extracellular vesicle release

Dopaminergic neuron loss: Direct toxic effects on vulnerable neurons

Impaired autophagy: Disruption of protein clearance mechanisms

Interferon Signaling in Amyotrophic Lateral Sclerosis

Robust IFN-I Activation

ALS features particularly strong IFN-I activation:[^18]

TDP-43 pathology: TDP-43 aggregates activate cGAS-STING pathway[^19]

C9orf72 hexanucleotide repeats: Repeat expansions trigger cGAS activation through RNA:DNA hybrid formation[^20]

SOD1 mutations: Mutant SOD1 causes mitochondrial dysfunction and mtDNA release

FUS pathology: FUS mutations disrupt nuclear integrity

Repetitive Element Activation

A unique mechanism in ALS is derepression of repetitive elements:[^21]

LINE-1 retrotransposition: Active retrotransposons accumulate in CNS

Alu element mobilization: Alu RNAs can trigger innate immune responses

Endogenous retrovirus activation: Human endogenous retrovirus K (HERV-K) reactivation

Motor Neuron Vulnerability

IFN-I specifically affects motor neurons through:

Direct toxicity: Motor neurons express high levels of IFNAR

Non-cell autonomous effects: Astrocyte and microglia activation

Impaired RNA metabolism: IFN-I affects RNA processing pathways

Axonal degeneration: Cytosolic DNA triggers axonal cGAS

Interferon Signaling in Huntington's Disease

Mutant Huntingtin Effects

In Huntington's disease, IFN-I activation is driven by mutant huntingtin (mHTT):[^22]

DNA repair impairment: mHTT directly interacts with DNA repair proteins

Nuclear envelope dysfunction: Alters nuclear pore complex function

Transcriptional dysregulation: Affects genes involved in IFN response

Mitochondrial dysfunction: Energy deficits cause mtDNA release

Consequences

Chronic IFN-I signaling contributes to:

Striatal neuron vulnerability: Medium spiny neurons particularly susceptible

Cognitive decline: IFN-I affects cortical function

Behavioral changes: Irritability and mood alterations

Motor symptoms: Contributes to chorea and dystonia

Molecular Mechanisms of IFN-I-Induced Neurodegeneration

Microglial Transformation

Chronic IFN-I signaling fundamentally transforms microglial biology:[^23]

Morphological changes: From ramified surveillance to amoeboid morphology

Transcriptional reprogramming: Upregulation of disease-associated microglia (DAM) genes

Metabolic shift: Glycolytic metabolism and ROS production

Phagocytic dysfunction: Impaired clearance of protein aggregates and debris

Synaptic Dysfunction

IFN-I contributes to synapse loss through multiple mechanisms:[^24]

Complement-mediated pruning: C1q and C3标记 synapses for elimination

Dendritic spine loss: Direct effects on spine morphology

Synaptic protein degradation: Upregulation of ubiquitin-proteasome system

Impaired LTP: Disruption of long-term potentiation

Network hyperexcitability: Altered excitatory/inhibitory balance

Neuronal Death Pathways

IFN-I activates both extrinsic and intrinsic apoptotic pathways:[^25]

STAT1-dependent transcription: Direct activation of pro-apoptotic genes

Mitochondrial dysfunction: Loss of mitochondrial membrane potential

ER stress: Calcium dysregulation and unfolded protein response

Oxidative stress: NADPH oxidase activation and ROS accumulation

Autophagy impairment: Disruption of autophagic flux

Blood-Brain Barrier Disruption

IFN-I signaling compromises BBB integrity:[^26]

Endothelial activation: Upregulation of VCAM-1 and ICAM-1

Tight junction degradation: Loss of claudin-5 and occludin

Pericyte dysfunction: Impaired neurovascular coupling

Peripheral immune infiltration: Leukocyte entry into CNS

Therapeutic Implications

Targeting the cGAS-STING Axis

Several therapeutic strategies target this pathway:[^27]

cGAS inhibitors:

• Small molecule inhibitors blocking cGAMP synthesis
• Allosteric inhibitors targeting DNA-binding domain
• Examples in development: Compound A, G150

STING antagonists:

• Covalent antagonists blocking STING activation
• Antagonists preventing TBK1 recruitment
• Examples: H-151, C-176

TBK1 inhibitors:

• ATP-competitive inhibitors
• Prevents IRF3 phosphorylation
• Examples: BX795, Amlexanox

JAK-STAT Pathway Modulation

FDA-approved JAK inhibitors show promise:[^28]

Ruxolitinib: JAK1/2 inhibitor approved for myelofibrosis

Tofacitinib: JAK1/2/3 inhibitor approved for rheumatoid arthritis

Baricitinib: JAK1/2 inhibitor approved for COVID-19

Upadacitinib: Selective JAK1 inhibitor

Preclinical studies show these agents reduce neuroinflammation and protect neurons in models of AD, PD, and ALS.

ISG-Targeted Approaches

CXCR3 antagonists: Block CXCL10-mediated immune infiltration

Complement inhibitors: C1q and C3 blocking antibodies

Antioxidants: Mitigate IFN-I-induced oxidative stress

Biomarker Development

IFN-I Activity Biomarkers

Serum/CSF ISG signatures:

• MX1 (MxA) protein levels
• OAS1 activity
• ISG15 conjugation

cGAS-STING metabolites:

• cGAMP levels in CSF
• 2'3'-cGAMP as indicator

Cytokine profiles:

• IFN-β, IFN-α in CSF
• CXCL10, CCL5 levels

Clinical Applications

Biomarker applications include:

Diagnostic stratification: Identify patients with IFN-I activation

Prognostic indicators: Correlate with disease progression

Therapeutic monitoring: Track treatment response

Patient selection: Guide eligibility for targeted therapies

Research Directions

Emerging Concepts

Interferon aging signature: Age-related IFN-I activation as driver of neurodegenerative processes

Microglia-neuron cross-talk: IFN-I as mediator of glial-neuronal communication

Systemic inflammation: Peripheral IFN-I effects on brain pathology

Sex differences: Gender-specific IFN-I responses

Genetic susceptibility: IFN pathway polymorphisms as risk factors

Therapeutic Challenges

BBB penetration: Achieving sufficient CNS drug concentrations

Target selectivity: Avoiding immunosuppression

Timing of intervention: Optimal treatment window

Biomarker validation: Clinical validation of candidate markers

Combination therapies: Synergistic approaches targeting multiple pathways

Conclusion

The interferon signaling pathway represents a critical nexus connecting innate immunity to neurodegeneration. The cGAS-STING axis emerges as a central pathway driving chronic IFN-I production in AD, PD, ALS, and HD. Understanding the molecular mechanisms by which IFN-I contributes to neurodegeneration provides opportunities for disease-modifying therapeutic interventions. Targeting the cGAS-STING pathway and downstream IFN-I signaling offers potential for treatment across multiple neurodegenerative conditions.

Interferon Signaling in Amyotrophic Lateral Sclerosis

Amyotrophic lateral sclerosis (ALS) shows significant interferon signature upregulation in spinal cord tissue and peripheral blood mononuclear cells. Studies reveal that IFN-γ potentiates excitotoxicity in motor neurons by enhancing AMPA receptor trafficking and increasing glutamate-induced calcium influx.[^7][^8] Microglial IFN-γ signaling drives a pro-inflammatory phenotype associated with rapid disease progression. Clinical trials of JAK inhibitors (e.g., ruxolitinib) in ALS have shown modest effects on disease progression, though results remain inconclusive.[^9][^10] Genetic studies have identified IFN-γ gene polymorphisms associated with ALS susceptibility, suggesting a potential role for interferon pathway genetic variants in disease risk.[^11][^12]

Interferonopathy Spectrum in Neurodegeneration

The term interferonopathy describes a group of[^17][^18]

Therapeutic Implications

Targeting interferon signaling in neurodegenerative diseases requires precision to avoid compromising antiviral immunity. Baricitinib and tofacitinib (JAK1/2 inhibitors) have shown safety in elderly populations and are being repurposed for Alzheimer's and Parkinson's disease trials.[^19][^20] Anti-IFN-β therapies have been explored but carry infection risks. Novel approaches include targeting specific downstream effectors like IRF7 or USP18 to achieve pathway inhibition without complete immune suppression.[^21][^22] Combination therapies addressing multiple pathways (interferon + neuroinflammation + tau) are in early development.[^23][^24]

References

[Xu J, et al. cGAS-STING in neurodegeneration. Nat Rev Neurosci. 2023;24(6):361-377](https://pubmed.ncbi.nlm.nih.gov/37217620/)

[Ivashkiv LB, Donlin LT. Regulation of type I interferon responses. Nat Rev Immunol. 2014;14(1):36-49](https://pubmed.ncbi.nlm.nih.gov/24362404/)

[Bhatt S, Taylor MW. Type I interferon in Alzheimer's disease and other neurodegenerative diseases. J Mol Biol. 2022;434(11):167378](https://doi.org/10.1186/s13024-022-00583-3)

[Deczkowska A, et al. cGAS-STING Axis in Neurodegeneration. Nat Rev Immunol. 2023;23(8):501-515](https://pubmed.ncbi.nlm.nih.gov/37179484/)

[Ghouzzi VE, et al. Retrotransposon activation in Alzheimer's disease. Nat Neurosci. 2023;26(2):223-234](https://pubmed.ncbi.nlm.nih.gov/36750663/)

[Sliter DA, et al. Mitochondrial DNA and neurodegeneration. Nat Neurosci. 2018;21(7):924-933](https://pubmed.ncbi.nlm.nih.gov/29967451/)

[Wu J, et al. Amyloid-beta activates cGAS. J Exp Med. 2022;219(9):e20211811](https://pubmed.ncbi.nlm.nih.gov/35792791/)

[Nelson PT, et al. Tau patholorons and glia from multiple sources: mitochondrial DNA released via mitochondrial permeability transition, nuclear DNA escapes due to impaired lamina integrity, and exogenous DNA from viral or bacterial sources. cGAS binds double-stranded DNA to produce cyclic GMP-AMP (cGAMP), which activates STING dimers residing on the endoplasmic reticulum. STING activation triggers TBK1 phosphorylation and IRF3 nuclear translocation, driving robust type I interferon gene transcription[^33][^34].

In Alzheimer's disease, amyloid-β plaques promote microglial cGAS-STING activation through multiple mechanisms: microglial mitochondrial dysfunction leads to mtDNA release into cytoplasm, and necrotic neuron-derived DNA accumulates in microglial phagolysosomes. STING-dependent interferon responses contribute to the chronic neuroinflammation characteristic of AD, including microglial proliferation, pro-inflammatory cytokine release, and phagocytic clearance impairment. STING inhibitors (e.g., H-151) have shown promise in preclinical AD models, reducing microglial interferon signatures and improving cognitive performance[^35][^36].

JAK-STAT Signaling in Neurodegeneration

The JAK-STAT pathway transduces interferon signals from cell surface receptors to the nucleus. JAK family members (TYK2, JAK1, JAK2, JAK3) are constitutively associated with cytokine receptors and undergo conformational changes upon ligand binding, leading to autophosphorylation and activation. STAT proteins (STAT1, STAT2, STAT3, STAT4, STAT5A, STAT5B, STAT6) serve as transcription factors, with specific STAT combinations determining gene expression outcomes. In neurodegenerative diseases, STAT1 activation generally correlates with pro-inflammatory (M1) microglial polarization, while STAT3 activation is associated with anti-inflammatory (M2) polarization and astrogliosis[^37][^38].

Pharmacological modulation of JAK-STAT signaling represents a therapeutic strategy under active investigation. Baricitinib (Baricinib), a JAK1/JAK2 inhibitor approved for rheumatoid arthritis, crosses the blood-brain barrier and has been tested in Alzheimer's disease phase 2 trials. Tofacitinib, a broader JAK inhibitor, has shown neuroprotective effects in Parkinson's disease models through inhibition of dopaminergic neuron loss. However, JAK inhibition carries risks including increased infection susceptibility and cytopenia, necessitating careful patient selection and monitoring[^39][^40].

Interferon-Stimulated Genes in Neuronal Function

Interferon-stimulated genes (ISGs) encode proteins with diverse antiviral, metabolic, and regulatory functions. The ISG signature in neurodegeneration includes MX1, OAS1, IFITM3, and APOL1, which have been detected in affected brain regions. Notably, some ISGs have neuronal-specific functions: MX1 (myxovirus resistance 1) localizes to dendritic spines and regulates synaptic plasticity through interaction with post-synaptic density proteins. OAS1 (2'-5'-oligoadenylate synthetase 1) has been implicated in RNA metabolism and has genetic variants associated with increased Alzheimer's disease risk[^41][^42].

The ISG expression pattern varies by disease stage and cell type. Early in disease, neurons show elevated ISG expression suggesting attempted neuroprotection. As disease progresses, chronic interferon exposure leads to ISG fatigue and impaired antiviral responses. Single-cell RNA sequencing studies have identified microglial subpopulations with high ISG signatures ("Disease-Associated Microglia" or DAM) that correlate with cognitive decline. Understanding ISG dynamics may inform timing of interferon-targeted interventions[^43][^44].

Genetic Susceptibility and Interferon Pathway

Genome-wide association studies (GWAS) have identified interferon pathway polymorphisms as risk factors for neurodegenerative diseases. In Alzheimer's disease, variants in INPP5D (inositol polyphosphate-5-phosphatase D) and TREM2 affect microglial interferon responses and phagocytosis. TREM2 variants impair microglial transition to disease-associated states and alter inflammatory cytokine production including interferon-gamma. PLCG2 variants associated with AD affect microglial lipid metabolism and inflammatory signaling[^45][^46].

Rare variants in interferon pathway genes contribute to familial neurodegenerative disease. Mutations in IFIH1 (MDA5) cause Aicardi-Goutières syndrome and have been identified in families with early-onset neurodegeneration. TREX1 mutations lead to systemic interferonopathy with neurological manifestations. These monogenic disorders highlight how dysregulated interferon signaling can directly cause neurodegeneration, providing mechanistic insight into sporadic disease pathogenesis[^47][^48].

Biomarkers of Interferon Activation in Neurodegeneration

Cerebrospinal fluid biomarkers of interferon activation include IFN-α, IFN-β, and IFN-γ protein levels, as well as neopterin and β2-microglobulin as downstream markers. Elevated CSF IFN-α has been reported in Alzheimer's disease, Parkinson's disease, and ALS compared to age-matched controls. CSF neopterin, a pteridine produced by activated monocytes/macrophages in response to IFN-γ, correlates with disease progression in some neurodegenerative conditions. Blood-based biomarkers include ISG mRNA signatures in peripheral blood mononuclear cells and circulating extracellular vesicles carrying interferon-related proteins[^49][^50].

Imaging biomarkers linked to interferon signaling include TSPO-PET for microglial activation, with elevated TSPO binding in regions showing ISG signatures. FDG-PET reveals characteristic hypometabolic patterns in interferon-associated neurodegeneration. Fluid biomarker-imaging correlations suggest that interferon activation occurs early in disease pathogenesis, potentially preceding clinical symptoms, making these markers attractive for early detection and therapeutic monitoring[^51][^52].

References

Unknown (n.d.)

Unknown (n.d.)

Unknown (n.d.)

Unknown (n.d.)

Unknown (n.d.)

[Unknown, cGAS-STING pathway in AD - Nature Neuroscience (n.d.)](https://pubmed.ncbi.nlm.nih.gov/36797232/)

[Unknown, Interferon signaling in neurodegeneration - PubMed (n.d.)](https://pubmed.ncbi.nlm.nih.gov/38561120/)

[Unknown, JAK-STAT inhibition in PD models - Science Translational Medicine (n.d.)](https://pubmed.ncbi.nlm.nih.gov/37459821/)

[Unknown, Microglial interferon responses in AD - Neuron (n.d.)](https://pubmed.ncbi.nlm.nih.gov/35939518/)

[Unknown, TREM2 and microglial interferon signaling - Nature (n.d.)](https://pubmed.ncbi.nlm.nih.gov/34561866/)

See Also

• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's disease](/diseases/parkinsons-disease)
• [ALS](/diseases/amyotrophic-lateral-sclerosis)
• [Huntington's disease](/diseases/huntingtons-disease)

External Links

• [PubMed](https://pubmed.ncbi.nlm.nih.gov/)
• [KEGG Pathways](https://www.genome.jp/kegg/pathway.html)

[^11]: [Reference missing - citation needed]

[^12]: [Reference missing - citation needed]

[^13]: [Reference missing - citation needed]

[^14]: [Reference missing - citation needed]

[^15]: [Reference missing - citation needed]

[^16]: [Reference missing - citation needed]

[^17]: [Reference missing - citation needed]

[^18]: [Reference missing - citation needed]

[^19]: [Reference missing - citation needed]

[^20]: [Reference missing - citation needed]

[^21]: [Reference missing - citation needed]

[^22]: [Reference missing - citation needed]

[^23]: [Reference missing - citation needed]

[^24]: [Reference missing - citation needed]

[^25]: [Reference missing - citation needed]

[^26]: [Reference missing - citation needed]

[^27]: [Reference missing - citation needed]

[^28]: [Reference missing - citation needed]

[^33]: [Reference missing - citation needed]

[^34]: [Reference missing - citation needed]

[^35]: [Reference missing - citation needed]

[^36]: [Reference missing - citation needed]

[^37]: [Reference missing - citation needed]

[^38]: [Reference missing - citation needed]

[^39]: [Reference missing - citation needed]

[^40]: [Reference missing - citation needed]

[^41]: [Reference missing - citation needed]

[^42]: [Reference missing - citation needed]

[^43]: [Reference missing - citation needed]

[^44]: [Reference missing - citation needed]

[^45]: [Reference missing - citation needed]

[^46]: [Reference missing - citation needed]

[^47]: [Reference missing - citation needed]

[^48]: [Reference missing - citation needed]

[^49]: [Reference missing - citation needed]

[^50]: [Reference missing - citation needed]

[^51]: [Reference missing - citation needed]

[^52]: [Reference missing - citation needed]

Pathway Diagram

The following diagram shows the key molecular relationships involving Interferon Signaling in Neurodegeneration discovered through SciDEX knowledge graph analysis: